Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932884 | 1.00 | TK1 (0.45) | TK1POLBALBPKMLMNA | |
| Ammonia Solution, Strong SCHEMBL2469226 | 0.99 | TK1 (0.45) | TK1POLBALBPKMLMNA | |
| Ammonia Solution, Strong SCHEMBL2469220 | 0.99 | TK1 (0.45) | TK1POLBALBPKMLMNA | |
| SCHEMBL2471155 | 0.91 | P2RY2 (0.40) | TK1POLB | |
| SCHEMBL2471150 | 0.91 | P2RY2 (0.40) | TK1POLB | |
| Ammonia Solution, Strong SCHEMBL2470903 | 0.90 | P2RY2 (0.40) | TK1POLB | |
| Ammonia Solution, Strong SCHEMBL2470896 | 0.90 | P2RY2 (0.40) | TK1POLB | |
| SCHEMBL932883 | 0.89 | TK1 (0.45) | TK1POLB | |
| Ammonia Solution, Strong SCHEMBL2469215 | 0.88 | TK1 (0.45) | TK1POLB | |
| SCHEMBL2469212 | 0.88 | F2 (0.46) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329318-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-25 | — | — | US | disclosed |
| US-20180111958-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2018-04-26 | — | — | US | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
| US-9695211-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160347780-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2016-12-01 | — | — | US | disclosed |
| EP-2370451-B1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES JAPAN INC (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9394333-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2451461-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | Ontorii, Inc (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | disclosed |
| EP-2370451-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | Chiralgen, Ltd. (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011005761-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF | ONTORII, INC (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010064146-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | CHIRALGEN, LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111958-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | TK1 239/4885POLB 96/4885ALB 2789/4885 |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | TK1 24/4885POLB 32/4885ALB 4518/4885 |
| US-10329318-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | PNP, ADAR, NUDT1 | TK1 239/4885POLB 96/4885ALB 2789/4885 |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | TK1 239/4885POLB 96/4885ALB 2789/4885 |
| US-20160347780-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | ADAR, PNP, NUDT1 | TK1 223/4885POLB 76/4885ALB 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.